Grace Therapeutics (GRCE) and Its Peers Financial Comparison

Grace Therapeutics (NASDAQ:GRCE) is one of 1,072 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Grace Therapeutics to similar businesses based on the strength of its earnings, dividends, analyst recommendations, risk, profitability, valuation and institutional ownership.

Insider and Institutional Ownership

6.1% of Grace Therapeutics shares are held by institutional investors. Comparatively, 44.0% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 13.5% of Grace Therapeutics shares are held by company insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Grace Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-20.10%	-17.10%
Grace Therapeutics Competitors	-3,399.87%	-235.11%	-32.77%

Risk and Volatility

Grace Therapeutics has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Comparatively, Grace Therapeutics’ peers have a beta of 3.84, suggesting that their average share price is 284% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Grace Therapeutics and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	0	0	1	0	3.00
Grace Therapeutics Competitors	8419	22270	50446	1350	2.54

Grace Therapeutics currently has a consensus target price of $12.00, indicating a potential upside of 541.71%. As a group, “Pharmaceutical preparations” companies have a potential upside of 259.14%. Given Grace Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Grace Therapeutics is more favorable than its peers.

Valuation & Earnings

This table compares Grace Therapeutics and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Grace Therapeutics	N/A	-$12.85 million	-1.61
Grace Therapeutics Competitors	$9.89 billion	$136.37 million	-5.49

Grace Therapeutics’ peers have higher revenue and earnings than Grace Therapeutics. Grace Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

Grace Therapeutics beats its peers on 7 of the 13 factors compared.

About Grace Therapeutics

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.